scPharmaceuticals Inc. (SCPH)
NASDAQ: SCPH · Real-Time Price · USD
2.775
-0.265 (-8.72%)
At close: Mar 28, 2025, 4:00 PM
2.832
+0.057 (2.05%)
After-hours: Mar 28, 2025, 7:56 PM EDT
scPharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for scPharmaceuticals stock have an average target of 14, with a low estimate of 12 and a high estimate of 18. The average target predicts an increase of 404.50% from the current stock price of 2.78.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for scPharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +332.43% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +548.65% | Mar 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +548.65% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +548.65% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +548.65% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
85.09M
from 36.33M
Increased by 134.20%
Revenue Next Year
169.67M
from 85.09M
Increased by 99.40%
EPS This Year
-0.95
from -1.91
EPS Next Year
0.15
from -0.95
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.2M | 213.9M | 352.0M | ||
| Avg | 85.1M | 169.7M | 254.7M | ||
| Low | 72.4M | 110.8M | 159.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 178.6% | 151.4% | 107.4% | ||
| Avg | 134.2% | 99.4% | 50.1% | ||
| Low | 99.2% | 30.2% | -6.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.55 | 1.25 | 2.16 | ||
| Avg | -0.95 | 0.15 | 1.40 | ||
| Low | -1.27 | -0.40 | 0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,313.7% | ||
| Avg | - | - | 815.0% | ||
| Low | - | - | 28.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.